Haga S B, Warner L R, O'Daniel J
Duke University, Institute for Genome Sciences and Policy, Durham, NC 27708, USA.
Public Health Genomics. 2009;12(3):158-62. doi: 10.1159/000189628. Epub 2009 Feb 10.
Pharmacogenetic testing holds great promise to improve health outcomes and reduce adverse drug responses through enhanced selection of therapeutic agents. Since drug responses can be manipulated by verbal suggestions, it is of particular interest to understand the potential impact of pharmacogenetic test results on drug response. Placebo and nocebo-like effects may be possible due to the suggestive nature of pharmacogenetic information that a drug will or will not likely lead to improved health outcomes. For example, pharmacogenetic testing could provide further reassurance to patients that a given drug will be effective and/or cause minimal side effects. However, pharmacogenetic information could adversely affect drug response through negative expectations that a drug will be less than optimally effective or cause an adverse response, known as a nocebo-like effect. Therefore, a patient's perceived value of testing, their understanding of the test results, and the manner in which they are communicated may influence therapeutic outcome. As such, physicians should consider the potential effect of pharmacogenetic test results on therapeutic outcome when communicating results to patients. Studies are needed to investigate the impact of pharmacogenetic information of therapeutic outcome.
药物遗传学检测有望通过优化治疗药物的选择来改善健康状况并减少药物不良反应。由于药物反应可受言语暗示的影响,因此了解药物遗传学检测结果对药物反应的潜在影响格外重要。由于药物遗传学信息具有暗示性,即某种药物可能或不可能改善健康状况,因此可能会出现安慰剂和反安慰剂效应。例如,药物遗传学检测可为患者提供进一步的保证,即某种特定药物会有效和/或产生最小的副作用。然而,药物遗传学信息可能会通过负面预期对药物反应产生不利影响,即认为某种药物效果欠佳或会引起不良反应,这被称为反安慰剂效应。因此,患者对检测的感知价值、他们对检测结果的理解以及结果的传达方式可能会影响治疗效果。因此,医生在向患者传达检测结果时应考虑药物遗传学检测结果对治疗效果的潜在影响。需要开展研究来调查药物遗传学信息对治疗效果的影响。